Key result
Pediatric heart failure management relies on diuretics and ACE inhibitors as first-line therapies, with heart transplantation or ventricular assist devices reserved for end-stage disease.
Why the study?
There is a lack of an equivalent consensus or well-established guidelines for the management of heart failure in children compared to adults.
This review provides a practical guide to the diagnosis and management of pediatric heart failure, highlighting the use of diuretics, ACE inhibitors, and advanced therapies like LVADs and transplantation.
Answers are grounded in this paper and cite their sources.
Novel pediatric HF data; leaves open optimal therapy selection pending randomized trials.
Pediatric heart failure represents an important cause of morbidity and mortality in childhood. Currently, there are well-established guidelines for the management of heart failure in the adult population, but an equivalent consensus in children is lacking. In the clinical setting, ensuring an accurate diagnosis and defining etiology is essential to optimal treatment. Diuretics and angiotensin-converting enzyme inhibition are the first-line therapies, whereas beta-blockers and devices for electric therapy are less used in children than in adults. In the end-stage disease, heart transplantation is the best choice of treatment, while a left ventricular assist device can be used as a bridge to transplantation (due to the difficulties in finding organ donors), recovery (in the case of myocarditis), or destination therapy (for patients with systemic disease).
No takes yet. Share an insight, caveat, or question.
Masarone et al. (2017) conducted a review in Pediatric heart failure. Pediatric heart failure management relies on diuretics and ACE inhibitors as first-line therapies, with heart transplantation or ventricular assist devices reserved for end-stage disease.
Synapse has enriched 10 related papers. Consider them for comparative context: